Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
19 Août 2021 - 2:00PM
InvestorsHub NewsWire
San Francisco, CA --
August 19, 2021 -- InvestorsHub NewsWire -- Oncology Pharma
Inc. (OTC:
ONPH) With much anticipation, Oncology Pharma, Inc. has
finalized a Co-Development Agreement with NanoSmart
Pharmaceuticals, Inc. Oncology Pharma will pursue the early
feasibility and nonclinical development of a dactinomycin
nanoemulsion drug product intended for the treatment of pediatric
cancer.
Oncology Pharma is
pleased to be moving forward with the development of its first
product based upon licensed technology in Oncology Pharma’s growing
portfolio of licensed intellectual property. Oncology Pharma’s
agreement with NanoSmart Pharmaceuticals will allow for continued
development of a proprietary lead-candidate formulation leading to
the submission of an Investigational New Drug application to the US
FDA. This phase of cancer drug development is intended to also
support potential applications in veterinary
oncology.
Oncology Pharma is
excited to be combining efforts with NanoSmart Pharmaceuticals to
pursue research and develop of improved treatments for pediatric
cancers.
ABOUT ONCOLOGY
PHARMA, INC.
ONCOLOGY PHARMA,
INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
ABOUT NANOSMART
PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held
California corporation that is developing nanoparticle drug
delivery platforms, including utilization of anti-nuclear antibody
(ANA) to target existing drug therapies to areas of necrosis
present in virtually all solid cancer
tumors.
FORWARD LOOKING
STATEMENTS
Certain of the
matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the
Company's business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include risks related to licensing
arrangements and joint ventures, including the need to negotiate
the definitive agreements for the relationships; possible failure
to realize anticipated benefits of business relationships, and
costs of providing funding to these business relationships. Other
risks and uncertainties relating to the Company include, among
other things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any
further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower
than expected sales and revenues; uncertain willingness and ability
of customers to adopt new technologies and other factors that may
affect further market acceptance; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; the Company's
ability to implement its long range business plan for various
applications of its technology; the Company's ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition; the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of the
Company's technology; management of growth; and, other risks and
uncertainties. This is not a solicitation to buy or sell securities
and does not purport to be an analysis of the Company's financial
position.
CONTACTS:
For additional
Information, please contact the Oncology Pharma
at:
One Sansome Street,
Suite 3500
San Francisco, CA
94104
Phone:
415-869-1038
Fax:
415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oncology Pharma (CE) (USOTC:ONPH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Oncology Pharma Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Oncology Pharma Inc (PK)